Tokyo, Japan

Keiko Kawabata

USPTO Granted Patents = 2 


 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2015-2017

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):

Title: Keiko Kawabata: Innovator in Pharmaceutical Research

Introduction

Keiko Kawabata is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of pharmaceutical research, particularly in the development of compounds that target 5-HT receptor-related diseases. With a total of 2 patents to her name, her work is paving the way for innovative treatments in various medical conditions.

Latest Patents

One of her latest patents involves a benzazepine compound that serves as an agent for treating or preventing 5-HT receptor-related diseases. This includes conditions such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and sexual dysfunction, including erectile dysfunction syndrome. The benzazepine compounds exhibit excellent 5-HT receptor agonist activity, making them valuable in addressing obesity and other related health issues.

Career Highlights

Keiko Kawabata is currently employed at Astellas Pharma GmbH, where she continues to innovate and contribute to the pharmaceutical industry. Her research focuses on the therapeutic potential of benzazepine compounds, which have shown promise in treating various medical conditions.

Collaborations

Throughout her career, Kawabata has collaborated with notable colleagues, including Hiroyuki Koshio and Norio Asai. These partnerships have enhanced her research efforts and contributed to the advancement of her projects.

Conclusion

Keiko Kawabata's work in pharmaceutical research exemplifies the impact of innovative thinking in medicine. Her contributions to the development of benzazepine compounds highlight her commitment to improving patient outcomes through scientific discovery.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…